menu
    • menu
    PHARMACOMPASS
    PHARMACOMPASS

    Grow Your Pharma Business Digitally
    X
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Olema Oncology Presents Updated Palazestrant Data at SABCS

    GLOBENEWSWIRE

    Novartis Kisqali Nataled Data Show Durable Breast Cancer Benefits

    GLOBENEWSWIRE

    Novartis Kisqali Natalee Data Show Durable Early Breast Cancer

    PR NEWSWIRE

    Novartis Kisqali® Approved for HR+/HER2- Early Breast Cancer

    GLOBENEWSWIRE

    Olema to Present Data on Palazestrant + Ribociclib at Symposium

    GLOBENEWSWIRE

    Novartis ribociclib recognized as Category 1 preferred breast cancer treatment

    GLOBENEWSWIRE

    Novartis Gets Positive CHMP Opinion For Kisqali® In Breast Cancer

    GLOBENEWSWIRE

    Novartis Gets Broad FDA Approval For Kisqali In Early Breast Cancer

    PR NEWSWIRE

    Relay Therapeutics Announces Positive Data For RLY-2608

    GLOBENEWSWIRE

    Novartis gears up for key expansions of 3 cancer drugs

    FIERCE PHARMA

    Novartis pauses enrollment for Kisqali breast cancer trials to align with nitrosamine guidelines

    PRESS RELEASE

    Alembic Pharma gets tentative USFDA nod for breast cancer drug

    ECONOMICTIMES

    Kisqali analysis reinforces 25% reduction in risk of recurrence of breast cancer

    GLOBENEWSWIRE

    Olema Announces Palazestrant Demonstrates Combinability with CDK4/6 Inhibitors

    GLOBENEWSWIRE

    Novartis puts Kisqali`s peak sales potential at above $7B

    FIERCE PHARMA

    Novartis showcases significant data updates from Kisqali, iptacopan and Scemblix

    GLOBENEWSWIRE

    Novartis Kisqali analysis reinforces reduction in risk of breast cancer

    GLOBENEWSWIRE

    Novartis drug cuts recurrence risk by 25% in early-stage breast cancer

    REUTERS

    Olema Oncology to Present at the 2023 Jefferies Healthcare Conference

    GLOBENEWSWIRE

    MSN Lab`s Generic Ribociclib Receives Receives Approval in the U.S.

    FDA

    MSN Lab Generic Letrozole:Ribociclib Receives Approval in the U.S

    FDA

    Novartis to present new data across oncology portfolio including Kisqali Ph III

    GLOBENEWSWIRE

    Novartis` Kisqali, Pluvicto top list of investor concerns

    FIERCE PHARMA

    Novartis buoyed by trial success in early-stage breast cancer

    REUTERS

    Natalee PIII trial demonstrates ribociclib reduces the risk of breast cancer

    GLOBENEWSWIRE

    Novartis Kisqali PFS benefit for pre- and perimenopausal patients with HR+/HER2

    PRNEWSWIRE

    Kesimpta surges as Kisqali starts to ramp at Novartis

    FIERCEPHARMA

    Kisqali increases OS in advanced breast cancer patients by 12 months

    EUROPEANPHARMACEUTICALREVIEW

    Novartis & SOLTI collaborate on HARMONIA, phase III study of Kisqali vs Ibrance

    PHARMABIZ

    Novartis to pit Kisqali against Ibrance in head-to-head trial

    FIERCEPHARMA

    Ribociclib/Endocrine Therapy Improves OS Regardless of Age in Advanced

    ONCLIVE

    Novartis` KISQALI product monograph in Canada now includes MONALEESA-3 data

    BIOSPACE

    Novartis Kisqali® demonstrates nearly five years median overall survival in MBC

    PRNEWSWIRE

    Novartis` MONALEESA-7 KISQALI® (ribociclib) study demonstrated significant

    NEWSWIRE

    Novartis Kisqali receives highest rating of any CDK4/6 inhibitor on the ESMO

    PHARMABIZ

    Novartis announces new late-breaking ofatumumab data at EAN

    GLOBENEWSWIRE

    AllianceRx Walgreens Prime studies the use of cyclin kinase 4/6 inhibs

    PR NEWSWIRE

    Novartis touts survival edge in Kisqali`s TV debut

    FIERCE PHARMA

    Novartis’ Kisquali bests AZ’ Faslodex in breast cancer trial

    PHARMA TIMES

    Novartis, Eli Lilly marquee positive survival data for CDK 4/6 franchises

    ENDPTS

    FDA Warns of Possible Interstitial Lung Disease, Pneumonitis,Breast Cancer Drugs

    CANCERTHERAPYADVISOR

    FDA warns about rare, severe lung inflammation with Ibrance, Kisqali, & Verzenio

    FDA

    Three Breast Cancer Drugs: FDA Warns of Rare but Serious Lung Inflammation

    RAPS

    NICE U-turn for Kisqali in breast cancer

    PHARMATIMES

    Novartis’ Kisqali, trailing Lilly’s Verzenio, nabs limited NICE backing

    FIERCE PHARMA

    U.K. drug discovery startup Healx taps GSK, Astex alum as CSO

    FIERCE BIOTECH

    Novartis’ Kisqali hits endpoints in Phase III breast cancer trial

    PHARMATIMES

    What to watch for, including Keytruda, Lynparza, KRAS and more

    FIERCE PHARMA

    Novartis exploring Saudi Arabia for production of cancer drugs

    FIERCE PHARMA

    Novartis’ Kisqali hit with NICE rejection

    PHARMATIMES

    NICE rejects Novartis` struggling breast cancer drug Kisqali

    FIERCE PHARMA

    NICE nod for Lilly’s breast cancer drug Verzenio via CDF

    PMLIVE

    NICE nod for Lilly’s breast cancer drug Verzenio via CDF

    PMLIVE

    EMA committee recommends approval for 4 medicine

    PHARMABIZ

    NICE rejects Eli Lilly`s Verzenio for breast cancer in draft guidance

    PHARMA FILE

    Lilly gets EMA nod for Verzenio in breast cancer

    PM LIVE

    Novartis considers filings for PI3K drug in breast cancer

    PMLIVE

    Merck`s Keytruda scores paramount nod in lung cancer

    FIERCE PHARMA

    Merck ‘real-time’ OK for Keytruda offers a peek at FDA`s data highway

    ENDPTS

    FDA Drafts 26 New Product Specific Guidances for Generic Drugmakers

    RAPS

    Copyright © 2025 LePro PharmaCompass OPC Private Limited, All rights reserved.